

1 Portland Street, P.O. Box 160 Saint John, N.B. E2L 3X9 Toll-free 1800 999-9775 Fax 506 632-2819 Web worksafenb.ca l, rue Portland, case postale 160 Saint John NB E2L 3X9 Sans frais 1800 999-9775 Télécopieur 506 632-2819 Web travailsecuritairenb.ca

Ketamine/Esketamine Review

Important Information

Please work through the following pages with your patient or the patient's chart as necessary. Fax completed documents to 1 888 629-4722. Keep the original in your chart / file.

l,	request full reimbursement for completing the Ketamine/Esketamine
Review booklet for my patient,	·
Physician name:	
Signature:	
Date:	
Payee Code:	

FOR QUESTIONS on completing this form please contact WorkSafeNB toll-free at 1 800 999-9775.



1 Portland Street, P.O. Box 160 Saint John, N.B. E2L 3X9 Toll-free 1 800 999-9775 Fax 506 632-2819 Web worksafenb.ca I, rue Portland, case postale 160 Saint John NB E2L 3X9 Sans frais 1800 999-9775 Télécopieur 506 632-2819 Web travailsecuritairenb.ca

Ketamine/Esketamine Approval, Documentation and Treatment Review Booklet

The Ketamine/Esketamine workbook must be completed by the treatment provider. It allows for systematic documentation and review of the ketamine/esketamine treatment process. The treatment provider is responsible to provide the required information in the Pre-Approval Request Section and submit prior to treatment authorization. The treatment provider is also responsible to complete the requested information in the Monitoring and Reporting Section and the Long-Term Reporting Section of the form as indicated.

Pre-Approval Request Section

- Upon receipt of the information in the Pre-Approval Request Section, WorkSafeNB will complete an internal review and provide a reference number if the treatment is approved.
- Please see page 3 of the review booklet.

Monitoring and Reporting Section

- The treatment provider completes this section of the form after each treatment session, documenting the patient's status.
- Please see page 4 of the review booklet.

Long-Term Reporting Section

- The treatment provider submits ongoing reports in this section of the form including Patient Health Questionnaire (PHQ-9), for long-term monitoring at baseline, 4-6 weeks, 3 months, 6 months and 9 months.
- Please see page 6 of the review booklet.

The physical and psychological monitoring and safety during each session are tracked in real-time, while ongoing monitoring and quarterly reviews ensure that the treatment is continuously evaluated for safety and efficacy.

Health care professionals must complete all sections of the workbook in full to ensure WorkSafeNB's standard for excellence in client care and patient safety.

Pre-Approval Request Section

treatment. Patient name: Date of birth: _____ Address: Phone number: Claim number: _____ Current risk of suicide: None Low Medium High Please provide baseline score of the <u>Patient Health Questionnaire (PHQ-9)</u>: _____ Please provide a list of prescriptions of first line psychotropics trialed in advance of treatment (attach or enter brief notes): Detailed treatment plan and justification: Expected outcomes and milestones: **CHECKLIST** Patient has an accepted compensable injury AND meets DSM-5-TR criteria for Major Depressive Disorder □ No exclusion criteria present (e.g., no psychotic disorder, bipolar disorder, OCD, Cluster B personality, active substance use disorder without a safety statement) Statement of safety submitted if applicable Treatment and monitoring plan provided and aligns with WorkSafeNB and billing standards Provider signature: _____ Date:

This form will be completed by the **treatment provider** to request pre-approval for ketamine/esketamine

Monitoring and Reporting Section

This section will be used by the trec	atment provider to report on each session after the pre-approval process.
SESSION CHECKLIST (treating nurse	or physician)
☐ Date and time of treatment sess	sion:
Cardiorespiratory monitoring log	g:
Pre-session vital signs recorded	I □ HR □ BP □ 02 stats □ RR
Continuous monitoring recorded	d 🗌 HR 🔲 BP 🔲 02 stats 🔲 RR
Post-session vital signs recorded	dHRBP02 statsRR
Attending healthcare profession	nals:
Airway management expert nar	me and credentials:
Signature confirming attendance	ce and patient stability:
PSYCHOLOGICAL MONITORING LOG	(treating nurse or physician)
Pre-session psychological state (a	ittach or enter brief notes):
Immediate post-session psychology transient dissociative symptoms—	gical state based on up to two hours of monitoring (note any observed attach or enter brief notes):
Adverse effects noted during sessi	on:
Patient's feedback:	
Patient Information:	
Patient name:	
Date of session:	Session number:

Physical and Psychological Monitoring:		
Physical condition stable during the session		
☐ No adverse reactions or side effects		
Psychological condition stable		
Evaluation of potential side effects:		
Additional notes:		
Provider signature:	Date:	

Long-Term Reporting Section								
Patient name:	rtient name:Date of report:							
			months					
Psychologic	al assessment reco ufenb.ca/media/6312	rd typewritten (trec 28/phq-9-test.pdf	ating doctor) (attac	ch the PHQ-9 test):				
Monitoring of impact: PHQ-9 scores since beginning treatment:								
	Baseline	4-6 weeks	3 months	6 months	9 months			
Date								
PHQ-9 Score								
Additional psyc	chological scores (if	applicable):						
Benefits seen c	and documented in	assessments:						
Changes in tre	atment plan:							
Provider comm	nents on progress:							
Provider signat	ure:		Date: _					